HighPoint Blog

Biosimilars are on the agenda of several players in the pharmaceutical industry. Several companies’ new leg of growth seems to be the creation of a biosimilar franchise. The question is “How real are the opportunities in an ever growing competitive environment?"

In the next 5 years, Biosimilars could hit the market to compete with some key biologics cumulating sales of more than EUR40 billion....

Read More

When we talk about open enrollment for January 1st activity, we tend to focus on the member-related situations that come during this time of new enrollments, disenrollments and benefit changes.   New benefit coverage requests will pour in and existing coverages will be modified, taxing your people and systems.  

Read More
Read More

Tag